Abstract: The present disclosure provides a C1q binding assay. The assay disclosed here determines theC1q binding affinity of antibody by using Biolayer interferometry (BLI) technique. The disclosed method does not require any labelling of antibody, and thus is a simple and robust method for determining the binding affinity of antibody to C1q protein. The binding affinity of an antibody to a C1q protein involves use of biosensors such as anti-Human Fab-CH1 (FAB2G) biosensors to capture and functionalize the antibody.
| # | Name | Date |
|---|---|---|
| 1 | 202447056199-STATEMENT OF UNDERTAKING (FORM 3) [23-07-2024(online)].pdf | 2024-07-23 |
| 2 | 202447056199-POWER OF AUTHORITY [23-07-2024(online)].pdf | 2024-07-23 |
| 3 | 202447056199-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [23-07-2024(online)].pdf | 2024-07-23 |
| 4 | 202447056199-FORM 1 [23-07-2024(online)].pdf | 2024-07-23 |
| 5 | 202447056199-FIGURE OF ABSTRACT [23-07-2024(online)].pdf | 2024-07-23 |
| 6 | 202447056199-DRAWINGS [23-07-2024(online)].pdf | 2024-07-23 |
| 7 | 202447056199-DECLARATION OF INVENTORSHIP (FORM 5) [23-07-2024(online)].pdf | 2024-07-23 |
| 8 | 202447056199-COMPLETE SPECIFICATION [23-07-2024(online)].pdf | 2024-07-23 |
| 9 | 202447056199-FORM 18 [26-07-2024(online)].pdf | 2024-07-26 |